StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
110020.KQ$1963.00-1.31%
Fair $1963.00+0.0%

110020.KQ

Jeonjinbio Co., Ltd.

Basic Materials / Specialty ChemicalsKOSDAQ

$1963.00

-26.00 (-1.31%)

Fairly Valued+0.0%Fair Value $1963.00Fund rank 25/100 · Data gapFallback financials|
SA 17/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-307.6M · quality 38.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 23/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is -1.1%, below the 5% threshold
Thesis & Journal · 110020.KQLocal privado en este navegador · Jeonjinbio Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$17.8B

P/E

N/A

•

EV/EBITDA

32.5x

↑

ROE

-1.1%

↓

Gross Margin

27.6%

↑

Debt/Equity

N/A

•
52-Week Range$1963
$1712$4480

TradingView lightweight chart

110020.KQ price, volumen y niveles de valoración

Último $1,963Periodo -83.2%
Fair value: $1,963

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+20.7%

FCF CAGR

—

FCF margin

-2.2%

FCF / Net income

1.57x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $13.69B · net income $-195.8M · FCF $-307.6M

2022-FY → 2025-FY

Gross margin

27.6%+1.9% pts

Operating margin

-2.5%+37.7% pts

Net margin

-1.4%+38.5% pts

FCF margin

-2.2%+72.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$13.69B$13.69B$19.27B$15.68B$7.79B
Net Income$-195.8M$-195.8M$4.35B$-6.44B$-3.11B
EBITDA$340.1M$340.1M$6.12B$-3.41B$313.8M
EPS-22.00-22.00505.00-884.00-473.00
Gross Margin27.6%27.6%31.4%31.1%25.7%
Operating Margin-2.5%-2.5%5.7%-7.9%-40.2%
Net Margin-1.4%-1.4%22.6%-41.1%-39.9%
Balance Sheet
Debt/Equity——0.010.900.62
Current Ratio10.4910.49———
Cash Flow
Free Cash Flow$-307.6M$-307.6M$2.61B$-972.2M$-5.84B
Returns
ROE-1.1%-1.1%24.6%-103.5%-32.5%
Valuation
P/E——4.85——
EV/EBITDA32.5232.522.43—84.69
P/B1.001.001.1910.312.29
Growth & Yield
Revenue Growth-28.9%-28.9%22.9%101.2%—
EPS Growth-104.4%-104.4%157.1%-86.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -12.4%

Total return

-12.4%

Start / end P/E

n/dx → n/dx

EPS bridge

505.00 → -22.00

Residual

-12.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-12.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.